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High-throughput experimental studies to identify miRNA targets
directly, with special focus on the mammalian brain
Peter T. Nelson, MD PhD, Marianthi Kiriakidou, MD, Zissimos Mourelatos, MD, Grace S. Tan,
PhD, Mary Jennings, Kevin Xie, and Wang-Xia Wang, PhD
Department of Pathology and Division of Neuropathology, University of Kentucky Medical Center
and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536
Abstract
We review the pertinent literature on methods used in high-throughput experimental identification
of microRNA (miRNA) “targets” with emphasis on neurochemical studies. miRNAs are short
regulatory non-coding RNAs that play important roles in the mammalian brain. The functions of
miRNAs are related to their binding of RNAs including mRNAs. Since mammalian miRNAs tend
to bind to target mRNAs via imperfect complementarity, understanding exactly which target mRNAs
are recognized by which specific miRNAs is a challenge. Based on early experimental evidence, a
set of “binding rules” for miRNAs has been described. These have focused on the 5’ “seed” region
of miRNAs binding to the 3’ untranslated region of targeted mRNAs. Bioinformaticians have applied
these algorithms for theoretical miRNA target prediction. To date, the different computational
methods are not in agreement with each other and do not explain all miRNA targets as defined using
high-throughput experimental methods. We consider these latter techniques which identify putative
miRNA targets directly. Each experimental approach involves specific assumptions and potential
technical pitfalls. Some of these direct experimental methods for miRNA target identification have
used co-immunoprecipitation (RIP-Chip and others) and transfection-based experimental design.
Topics related to experimentally identified miRNA targets are discussed, with special emphasis on
studies pertinent to the mammalian brain.
Introduction
MicroRNAs (miRNAs) are ~22 nucleotide (nts) non-coding RNAs that play fundamental roles
in the most animal tissues including the human brain (Ambros, 2004; Kosik, 2006).
Functionally, miRNAs “target” mRNAs through partial hybridization, leading to changes in
the rate of cognate polypeptide formation. miRNAs interact with mRNAs within
microribonucleoparticles (miRNPs) which contain both protein and RNAs (Mourelatos et al.,
2002). Also in miRNPs, Argonaute (AGO) proteins bind directly to mature miRNAs. Four
paralogous mammalian AGO proteins (AGOs 1-4) help orchestrate miRNA activities (Carmell
et al., 2002; Hammond, 2005; Sasaki et al., 2003). A single miRNA, in association with AGO
proteins, may target hundreds of different mRNAs. In the majority of cases, miRNAs silence
gene expression by translational repression and RNA degradation. There are many molecular
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mechanisms that occur downstream of the miRNA:mRNA interaction, and these mechanisms
may differ in particular species, tissues, and cells (Iwasaki and Tomari, 2009; Kiriakidou et
al., 2007; Liu et al., 2008; Morris, 2008; Parker et al., 2006; Saetrom et al., 2007; Tan et al.,
2009a).
The goal of this review is to discuss studies that use high-throughput techniques to identify
putative miRNA targets (PmiTs), with emphasis on studies pertinent to the human brain. For
the sake of this review, a PmiT is a mRNA that is bound to by a specific miRNA with decreased
cognate polypeptide as a result (whatever the exact downstream mechanism). The reason that
we use the word “putative” is that the miRNA targets identified by these techniques generally
need to be validated using other, more labor-intensive, methods. Since each experimental
method has its own assumptions, strengths, and weaknesses, these data need to be assessed
with critical scrutiny. There is multi-layer regulatory complexity in vivo, including different
levels of transcript processing and modifications, multiple subtypes of noncoding RNA,
complex RNA binding protein biochemistry, and many other biological signals. These are of
course distinct from the technical experimental limitations affecting researchers who attempt
to identify physiological miRNA targets. Note that many of the studies that are referred to were
in systems not directly related to the mammalian brain. We assume that many of the lessons
learned from those systems can have at least indirect relevance to the many researchers who
are thinking of experimental strategies to study mammalian brain PmiTs.
The “binding rules”
Just as important as discovering individual miRNAs’ targets is characterizing the over-arching
biochemical principles that govern how miRNAs interact with target mRNAs with particular
reference to the molecules’ sequence complementarity. We term these the “binding rules” for
the sake of brevity. Binding rules are pivotal because if one understood completely how
miRNAs interact with mRNAs then it would be possible to predict confidently the strength of
individual interactions. An extensive amount of work has been performed in this area and
further studies are ongoing (see for example (Alexiou et al., 2009b; Bartel, 2009; Hon and
Zhang, 2007; Kiriakidou et al., 2004; Rajewsky, 2006)).
In animals, miRNAs tend to bind via imperfect complementarity making target prediction
difficult. Nonetheless, certain tendencies have emerged. Studies to date have focused primarily
on specific sequence determinants of the miRNA and the mRNA:
1> The “5’ seed” (nts #2-7 from the 5’ end) portion of miRNAs
2> The 3’ untranslated (UTR) portion of mRNAs
According to these ideas (with the support of a large amount of experimental data including
recent high-throughput proteomics data (Baek et al., 2008; Orom and Lund, 2009; Selbach et
al., 2008)) a given PmiT is “downregulated” if a 6nts sequence in its 3’UTR is complementary
to a 5’ seed region of a co-expressed miRNA. These binding rules are by no means absolute
but they provide a common point of consensus among many experimental and computational
experts in the field.
Computational methods: progress and limitations
If the above binding rules were applicable in every instance, then mammalian miRNA target
prediction would have been solved and all computational methods would be essentially
identical. But such is not the case. Computational methods for miRNA target prediction are in
constant refinement. The evolution of computational methods occurs at many levels including
within individual groups’ methodology and also due to new groups and methodologies coming
(literally) on-line. For reviews on the subject of computational miRNA target prediction, see
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(Alexiou et al., 2009a; Barbato et al., 2009; Berezikov et al., 2005; Brown and Sanseau,
2005; Maziere and Enright, 2007; Miranda et al., 2006; Robins et al., 2005; Watanabe et al.,
2007).
Some actual miRNA targets are not predicted or explained using existing computational
methods. There is also some question whether any “one size fits all” computational prediction
algorithm is valid that ignores potential idiosyncrasies of different organisms, cells, tissues,
genes, and miRNA families. Well-documented miRNA:mRNA pairs have been described that
would not be predicted by most current computational methods (Didiano and Hobert, 2006;
Rigoutsos, 2009). Even within a mRNA’s 3’UTR there are many complexities in terms of
sequence determinants, tertiary structure, protein interactions, and/or alternative splicing
events. Finally, miRNA-based regulation is not generally an “all-or-none” phenomenon
(Bartel, 2009; Su et al., 2009; Ying and Lin, 2005) and the ability for computational methods
to predict the strength gradations of miRNA binding and/or miRNA “activity” is currently
debated.
These concerns do not diminish the relevance and importance of computational approaches to
miRNA target prediction. Computational algorithms are and will remain an important tool for
miRNA researchers. However, in order to help refine and strengthen these algorithms in the
context of small regulatory RNA science, more experimental studies are required.
Methods for simultaneous identification of multiple putative miRNA targets
High throughput methods for identifying PmiTs have been invented utilizing a variety of
experimental technologies and contexts (Orom and Lund, 2009). An overview of these studies
is presented (Table 1). However, a few common denominators have emerged. First, most
methods work through isolating target mRNAs that are bound to miRNAs. Secondly, there
must be some high-throughput method for correlating and cataloging the miRNA-bound
mRNAs that are (relatively) specific to individual miRNAs. The target profiling techniques
have involved various types of arrays, deep sequencing, and proteomics techniques.
To isolate mRNAs that are bound by miRNAs, many studies have used co-
immunoprecipitation (co-IP) based methods, often with downstream microarrays to profile the
target mRNAs (this approach can be termed “RIP-Chip”(Keene et al., 2006)). For these
experiments, an antibody has tended to be used in the co-IP which means that a protein must
be recognized. The co-IPed protein usually has been AGO protein(s), which directly embrace
pre-miRNAs and mature miRNAs along with target mRNAs. Some studies have employed
“tagged” AGO proteins. For a list of PmiT studies using co-IP approaches, along with pertinent
additional details, see Table 1.
miRNA transfection is another technique that has been widely used in experiments for high-
throughput identification of PmiTs. miRNA transfection usually requires some sort of
membrane perturbation that enables the small polynucleotides to enter the cells and to become
incorporated into the miRNA processing machinery. This technique is especially relevant to
PmiT prediction because it allows researchers to control for the dominantly expressed miRNA
in the cell of interest. By comparing the target mRNA repertoire in cells with different miRNAs
transfected, the PmiTs can be predicted to be due to that differential miRNA expression. Note
that in some of the studies (Table 1), both co-IP and transfections were utilized. It should also
be noted that transfection or overexpression of exogenous miRNAs resembles a straightforward
siRNA experiment with unpredictable downstream events (see below). For this reason, miRNA
depletion approaches (Cheng et al., 2005;Horwich and Zamore, 2008;Krutzfeldt et al.,
2005;Orom et al., 2006) could provide effective additional functional information about
physiological target sites.
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Where can one access experimentally derived PmiTs, and, what insights have the
abovementioned studies provided about PmiTs? Some public domain web-based data
repositories are available that provide data on experimentally identified PmiTs (for example,
see (Hammell et al., 2008; Hsu et al., 2006; Lall et al., 2006; Sethupathy et al., 2006)). Note
that there are many more data about experimentally identified PmiTs within papers and in
“supplemental materials” on published works such as those in Table 1. In the future we may
be able to incorporate all these data in meta-level research projects, along with some sort of
methods to compare strengths and weaknesses of various approaches. We discuss below some
of the important themes and interesting questions that have emerged from the very large amount
of data in these important studies.
Common assumptions in high-throughput PmiT identification studies
The studies enumerated in Table 1 provide data directly relevant to how miRNAs target
mRNAs and which miRNAs bind to which mRNAs. However, there is some question as to
whether those studies adequately capture and convey the complexity of their subject. Here are
a handful of common assumptions that probably merit some attention in terms of interpreting
prior studies and designing future ones.
Generalizability of findings in individual experimental systems
Much of the gene expression regulation (transcription, translation, splicing, etc.) machinery
are similar even across phylogenetically divergent species. It is thus unlikely, for example, that
an entirely distinct miRNA regulatory mechanism would evolve in the course of primate
evolution. On the other hand, there are some key differences in how miRNAs work across
different animal species, as there are quite different paradigms at work in plants. Some aspects
of miRNA biochemistry have been shown to be species-specific (Berezikov et al., 2006;
Landthaler et al., 2008; Mourelatos et al., 2002; Zhang et al., 2008). Specific mammalian tissue
and cell types (sperm cells being the best example) have their own subtypes of small regulatory
RNAs and their own AGO-like proteins (Aravin et al., 2006). It seems as though the miRNA
molecular machinery is a platform with an exceptional potential for complex and multimodal
gene expression regulation that includes transcriptional and translational control. For example,
some – but not all – human miRNAs and AGO proteins are now known to reside in the nucleus
and bind DNA although nuclear miRNA biochemistry is still poorly understood (Guang et al.,
2008; Kim and Rossi, 2009; Tan et al., 2009a). We and others have hypothesized that the
miRNAs and other noncoding RNA have served as a “complexity multiplier” in the evolution
of the fantastically complex primate brain (Heimberg et al., 2008; Mehler and Mattick, 2007;
Nelson and Keller, 2007). Thus, as our comprehension of the full potential of miRNA-based
gene regulation expands, it is likely that some mechanisms will differ based on specific
parameters related to species, cell types, developmental stages, environmental stimuli, etc.
Physiological relevance of tumor cell lines
Tumor cell lines have been a mainstay experimental context of studies that use high-throughput
methods to identify new PmiTs (see Table 1). Clearly, there are extremely compelling reason
to use these well-characterized, clonal cells for easily replicable hypothesis testing and robust
data generation. However, there are also good reasons to reflect on the characteristics of tumor
cell lines: they are neoplastic; they tend to have extensive chromosomal abnormalities; and
they are selected for particular characteristics (robustness, transfectability, plate adherence,
etc) that are divorced from physiological normalcy. Their very survival and passage in culture
is evidence of stark differences relative to most normal cells. In sum, they are non-physiologic.
Tumor cells tend to have suppression of miRNA expression and/or modification of miRNA
processing proteins (Adams et al., 2009;Chung et al., 2009;Ciafre et al., 2005;Guo et al.,
2009;Wijnhoven et al., 2007). Thus it is possible that an over-reliance on tumor cell line studies
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has introduced biases in the study of PmiTs: we may be missing entire physiological pathways
and we may be witnessing evidence of some cancer-specific biochemical pathways of dubious
correlation to that of healthy cells in situ. For most relevance to human brain, it may be best
experimentally to try different clonal cell lines including human cells and cells with neuronal
phenotype.
Co-immunoprecipitation experiments with tagged Argonaute proteins
At least a half-dozen of the important studies that have described experimentally derived PmiTs
have used co-IP experiments with tagged AGO proteins (see Table 1). The protein tags have
varied and include MYC, FLAG, and HA peptide tags. A common assumption underlying
these studies is that the tagged AGO function analogously to the non-tagged AGO, or, if there
is a difference, the tagged AGO does not systematically alter the distribution of miRNAs
incorporated or mRNAs targeted. This is not necessarily a safe assumption. We have found
that tagged AGO in some cancer cell lines may be loaded with fewer endogenous miRNAs
(see Figure 1 and unpublished data). For some of the experiments, there is a possibility that
this may introduce currently unknown systematic biases.
Alternative miRNA mechanisms and stability of Argonaute-miRNA-mRNA interactions
Most of the methods used to derive PmiTs experimentally with high-throughput methods
require for there to be some sort of stable association between AGO, miRNA, and targets.
These miRNP complexes are then washed until only the miRNP remains and then the targets
are profiled. It is very possible that a subset of miRNAs and/or targets have more transient
interactions that do not survive the washing steps. These might introduce another source of
bias. As a potential example of this, we have found that miR-107 seems to target both GRN
and BACE1 mRNAs; however, only GRN mRNA is found enriched in the AGO-miRNP after
washing (see below). Some methods of high-throughput PmiT identification would side-step
the dependence on stable miRNA:mRNA interaction, most notably the HITS-CLIP method
that uses ultraviolet (UV) cross-linking and downstream identification of miRNA-bound
mRNAs (see below). However, even this method has some technical assumptions.n In the
outstanding mouse brain HITS-CLIP study, the miRNA most frequently UV “CLIPed” was
mmu-miR-30e, which is not known to be among the top 10 most frequent brain miRNAs (Chi
et al., 2009).
Downregulation after miRNA transfection is due to specific targeting by the transfected
miRNA
miRNA transfections lead to a large number of downstream changes including transcriptional
regulation, widespread splicing changes, and others (see for example the work of (Khan et al.,
2009; Makeyev et al., 2007)). These downstream effects, not directly linked to miRNA
function, include dramatic shifts in the cellular mRNA and protein profiles. Thus secondary
expression pattern changes are admixed with the primary mRNA targeting and it is a challenge
to identify precisely which of these is which. Most studies note that predicted miRNA targets
are enriched among the population of mRNAs downregulated after miRNA transfection
(following the work of (Lim et al., 2005)). When we perform RIP-Chip experiments after
miRNA transfections, we use downstream microarray analyses to assess for enrichment in
AGO-miRNPs. Also, for each sample we also assess the lysates prior to the anti-AGO co-IPs.
Thus we can detect the mRNAs that are changed in expression that are not enriched in the
AGO-miRNPs. Consistently, we find that the large majority of mRNAs with altered expression
after miRNA transfection are not found enriched in AGO-miRNPS according to the RIP-Chip
analyses (see figure 2). These mRNA changes can be important, such as in the case of miR-125b
targets identified by the Lodish Lab in neuroblastoma cells (Le et al., 2009). However, it may
in some circumstances be incorrect to hypothesize that genes downregulated after miRNA
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transfected are AGO-bound direct miRNA targets. This concern provides another technical
reason that the HITS-CLIP experimental approach is advantageous because it more directly
identifies miRNA targets.
“The binding rules”—a reconsideration
Another assumption that deserves critical scrutiny is that all miRNAs bind according to similar
“rules”. For example, since the 5’ “seed” region of miR-124 and let-7a help to drive the
specificity of those miRNAs to their target mRNAs, does the 5’ seed also serve as the basis
for all other miRNAs’ binding? These assumptions seem quite appropriate when one considers
the near universality of some other nucleic acid binding/activity determinants, such as TATA
boxes, tRNA anti-codon sequences, and exon/intron junction-enriched sequences. However,
there are also reasons to speculate that there could be variations in how individual miRNAs
target their mRNAs. For example, the aggregate impact of 3’UTR A/U sequences, RNA tertiary
structure, local RNA-binding proteins, and other idiosyncrasies could functionally determine
particular miRNA targets. There are also important questions about the 3’ portion of miRNAs.
Why should a miRNA such as mir-124 or let-7a be absolutely conserved in every known animal
if the mid-portion and 3’ portion were not critical to its function? More to the point, there are
now experimentally validated examples where the 3’ portion of the miRNA are critical in
mRNA targeting (Bartel, 2009).
If there are cell and tissue-specific determinants of specific miRNA and mRNA targets, there
must be explanations for each biologic context. Testable hypotheses can be developed to
explain differing apparent binding rules for individual miRNAs. miRNAs comprise only a
small portion of miRNPs and other determinants such as the cell type-specific RNA binding
proteins (AGO is only one of the many miRNP-associated proteins (Mourelatos et al., 2002))
and mRNA repertoire are critically important to gaining a fuller picture of miRNA targeting.
Some miRNAs are spatially trafficked specifically to particular parts of the cell (nucleus versus
cytoplasm, and dendrites versus axons, for example) and these compartmental differences
might be accompanied by differing target determinants (Kye et al., 2007; Smalheiser, 2008a;
Smalheiser and Lugli, 2009; Tan et al., 2009a).
Brain-specific issues
The issues of specialized cell compartmentalization and miRNA biochemistry may be
supremely relevant in the mammalian brain. Nerve cell geometry -- with extreme distances
between cytoplasmic compartments and the cell nuclei -- and the potential importance of highly
localized activity-dependent translational control, are a few reasons why we and others have
speculated that miRNAs and other noncoding RNAs may play special roles in the brain (Kosik
and Krichevsky, 2005; Mehler and Mattick, 2007; Nelson et al., 2008). In the mammalian
brain, synaptic structures may harbor special machinery for miRNA processing (Edbauer et
al.; Smalheiser, 2008b). Roles for miRNAs in brain cell development and cell fate
determination are well-established but this field is still in rapid flux (Dugas et al.; Fineberg et
al., 2009; Krichevsky et al., 2006; Zhao et al.).
Relatively many of the prior studies using high-throughput methods to identify PmiTs have
studied “nervous system-specific” miR-124 (see Table 1). However, fewer experiments have
used an experimental system that included actual neurons, astrocytes, or other cell type
associated with the brain. A column in Table 1 indicates specific papers that are relevant to
high-throughput PmiT identification in mammalian brain-related cells. Space is insufficient to
describe in detail each of the excellent papers on miRNA targets relevant to the mammalian
brain, but several reports are discussed below.
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A particularly outstanding study on mouse brain (also referred to above) was from Robert
Darnell’s lab, using HITS-CLIP (Chi et al., 2009; Licatalosi et al., 2008). This approach
allowed for direct identification of specific target sequences targeted in mammalian brain. The
targeted sequences were identified using deep sequencing, rather than via microarray analyses
such as are used in other experimental paradigms. The targeted sequences included mostly 3’
UTR portions (~40% of targets), but also coding sequences (CDS; 25% of targets), and introns
(14% of targets). This study showed that there is a ~45-60nts AGO “footprint” of protected
sequence when a mRNA is bound to by miRNAs and AGO. The HITS-CLIP data also provided
the bases for some intriguing dissection of miR-124 targets in the mammalian brain. Further,
the authors provided some “ternary maps” of AGO-miRNA-mRNA interactions related to the
CLIPed miRNAs and mRNAs. These analyses provided some stimulating ideas about the
pathways and neurochemical systems whose regulation is influenced by miRNAs in
mammalian nervous systems. Surely we can anticipate future revelations about mammalian
brain function and miRNA neurochemistry using this outstanding methodology.
We recently used anti-AGO RIP-Chip experiments in the H4 “glioneuronal” tumor cell line
(Arnstein et al., 1974) after miRNA transfections for high-throughput identification of PmiTs
(Wang et al., 2010). For these experiments, it was assumed that a tumor cell line has at least
some physiological relevance, and that there is a stable interaction between AGO, miRNAs,
and some target mRNAs. A subset of nervous system-enriched miRNAs were evaluated
(miR-107, miR-124, miR-128, and miR-320). These experiments helped confirm that miRNAs
have strong global impact on gene expression, because miRNA transfection led to large shifts
in the mRNA repertoires. The changes included alteration in the miRNA machinery itself:
miR-107 and miR-128, but not miR-320, miR-124, or a control miRNA, led to downregulation
of AGO itself and a shift of miRNAs away from the AGO-miRNP.
Anti-AGO RIP-Chip experiments may also discover novel miRNA effects. We previously
found that miR-107 is downregulated in Alzheimer’s disease cerebral cortex (Wang et al.,
2008); this observation was recently validated in a new dataset using well-characterized human
brains (Wang et al, In Press). Having found that miR-107 targets BACE1 mRNA, which has
also been validated by an independent laboratory (Davidson et al., 2009), we wanted to identify
additional miR-107 targets using an unbiased high-throughput method. Surprisingly, using the
anti-AGO RIP-Chip approach we found that GRN mRNA is the strongest target for miR-107
in H4 cells despite the fact that computational algorithms did not predict binding (Wang et al,
In Press). The discrepancy correlates with the observation that miR-107 targets sites in the
CDS of GRN mRNA. This novel discovery may be relevant to neurodegenerative disease, brain
inflammation, neurotrauma, and neoplasia in the mammalian brain and elsewhere. Future high-
throughput PmiT studies will no doubt produce many such surprises as we refine our
understanding of miRNA neurochemistry.
Summary
MiRNA research is a dynamic field with an ever-expanding experimental toolkit. New
techniques have been invented and applied for direct, high-throughput experimental
identification of PmiTs. These experiments help to characterize the miRNA binding rules in
ever greater detail, which in turn help to guide computational algorithms. Many of these data
are now available in public domain websites. Although direct experimental PmiT identification
is extremely important, there are key assumptions made that should be considered carefully:
for example, the generalizability of the results across different species and cell types; the
relevance of tumor cell lines and/or tagged AGO proteins; the possibility of alternative
AGO:miRNA mechanisms; and the possibility that different miRNAs can be processed by
different binding proteins or cell compartments and thus according to different binding rules.
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Despite these caveats, PmiT identification can be vitally important, especially in the context
of the mammalian nervous system where miRNAs may have special relevance.
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Figure 1.
Urea-PAGE gel showing 3’-end radiolabeled RNA after co-immunoprecipitation (Co-IP)
experiments in human embryonic kidney 293T cells. These experiments show that the levels
of miRNAs loaded on overexpressed FLAG-tagged Ago2 are markedly reduced compared to
miRNAs loaded onto endogenous Agos. Lane 1: Nucleotide marker. Lane 2: 2A8 RNA co-IP
from nontransfected HEK 293T cells (2A8 antibody recognizes endogenous Agos). Double
arrowhead is two microRNAs ligated together, an artifact after labeling with T4 RNA ligase
and pCp. Asterisk shows pre-miRNAs (Tan et al., 2009a). Lane 3: anti-FLAG RNA co-IP from
293T cells transfected with empty FLAG vector (FLAG-mock). Lane 4: anti-FLAG RNA co-
IP from 293T cells transfected with FLAG-AGO2. Note that the pattern of bands in Lane 4 is
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quite distinct from that in Lane 2. Specifically, there is an accentuated band (corresponding to
[mt]tRNA-met) (Maniataki and Mourelatos, 2005), but by contrast the miRNA bands show
much less RNA in the FLAG-AGO co-IP.
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Figure 2.
Chart shows the number of mRNAs with at least 4-fold change in AGO-miRNP (red) and lysate
(blue) after specific mIRNA transfections. This provide some idea about the “downstream”
effects of some miRNAs and how individual miRNAs can have distinct effects. Experiments
were performed in H4 cells, a “glioneuronal” tumor cell line. All experiments were performed
in triplicate as described in detail previously (Wang et al., 2010). Note that for miR-107 and
miR-124, many more mRNAs are downregulated after miRNA transfection than are knocked
down in the lysate; however, for miR-320 this tendency is reversed. These data indicate that
individual miRNAs may act via different mechanisms. Fold-changes were determined with
respect to a transfected miRNA relative to control miRNA.
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